Cigna

Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
목요일, 5월 9, 2024
Vonoprazan/amoxicillin, Table, FDA, DTC, Pharmacy, Gastrointestinal disease, NERD, NDA, Hercules, Amazon Prime Video, Food, Research, Webcast, Business, Forecasting, Prescription, Cigna, PPI, PDUFA, Tablet, Patient, Physician, Ratio, Enzyme inhibitor, DDW, Marketing, Vonoprazan/amoxicillin/clarithromycin, Heartburn, Hulu, GERD, Clinical trial, GAAP, Growth, Overalls, Eosinophilic esophagitis, Pharmaceutical industry

ET

Key Points: 
  • ET
    FLORHAM PARK, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today reported financial results for the first quarter of 2024, and provided recent business highlights.
  • A reconciliation of the GAAP financial results to non-GAAP financial results is included in the tables below.
  • Phathom will host a conference call and webcast to discuss its first quarter financial results and business highlights today, May 9, 2024, at 8:30 a.m.
  • Phathom believes the presentation of these non-GAAP financial measures provides useful information to management and investors regarding Phathom's results of operations.

Oscar Health Announces Results for First Quarter 2024

Retrieved on: 
화요일, 5월 7, 2024
Professional Services, Health, Health Technology, Insurance, Health Insurance, Managed Care, Table, Total, Hospital, Cigna, Annual report, Security (finance), Partnership, Care Act 2014, Webcast, Ratio, Physician, Health care, Failure, Adjustment, Affordable Care Act, GAAP, Growth

A member covered under more than one of our health plans counts as a single member for the purposes of this metric.

Key Points: 
  • A member covered under more than one of our health plans counts as a single member for the purposes of this metric.
  • Oscar will host a conference call to discuss the financial results today, May 7, 2024, at 8:00 a.m. (ET).
  • A live audio webcast will be available via the Investor Relations page of Oscar’s website at ir.hioscar.com.
  • New factors emerge from time to time, and it is not possible for us to predict which will arise.

PracticeTek Appoints Steve Auerbach as New Chief Executive Officer

Retrieved on: 
화요일, 5월 7, 2024
Practice Management, Technology, Professional Services, Managed Care, Health, Payments, General Health, Health Technology, Software, Internet, Finance, UnitedHealth Group, Cigna, Optum, Light-year, Insurance, Lightyear Capital, Partnership, Acquisition, Management

PracticeTek, a leading provider of software, payments and billing solutions to the retail healthcare market, has announced that Steve Auerbach has been named Chief Executive Officer, effective May 1, 2024.

Key Points: 
  • PracticeTek, a leading provider of software, payments and billing solutions to the retail healthcare market, has announced that Steve Auerbach has been named Chief Executive Officer, effective May 1, 2024.
  • “I am thrilled to accept the role as Chief Executive Officer of PracticeTek,” said Steve Auerbach.
  • I look forward to working closely with the PracticeTek team to create an industry-leading platform for our customers.”
    “We are excited to have Steve join PracticeTek as Chief Executive Officer,” said Michal Petrzela, Managing Director at Lightyear Capital, which owns majority stake in the Company.
  • We are pleased to welcome Steve and are confident that his experience will enable him to build off PracticeTek’s strong foundation to significantly grow the company.”

Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors

Retrieved on: 
화요일, 5월 7, 2024
Hampton Roads, University, Executive, Blue Shield, Cigna, Elevance Health, SHP, Mid-Atlantic (United States), Venture round, Executive Committee, Commerce, AHIP, Certified Public Accountant, Management

NEW YORK, May 7, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the Company has closed a Series B-1 Preferred Stock offering led by one of the Company's long-time institutional investors, with gross proceeds of $11.6 million, bringing the total Series B / B-1 gross proceeds to $29.8 million. The offering provides the Company with significant working capital to execute its business plan as it approaches critical reimbursement milestones. The Company also announced that its Board of Directors has appointed healthcare industry veteran Dennis Matheis to serve as a Director, effective May 6, 2024.

Key Points: 
  • The Company also announced that its Board of Directors has appointed healthcare industry veteran Dennis Matheis to serve as a Director, effective May 6, 2024.
  • We are extremely fortunate that Dennis Matheis, a leading industry figure, has agreed to join the Lucid team."
  • Previously, in March 2024, the Company closed on $18.6 million in gross proceeds from a Series B Preferred Stock offering on comparable terms.
  • With this Series B-1 closing, Lucid has now completed its approximately $30 million, Board-approved Series B Preferred Stock offering.

Inclusive Workforce Pathways Emerge as the Cornerstone for Corporate Resilience

Retrieved on: 
목요일, 5월 2, 2024
Education, Salesforce, Organization, The Coca-Cola Company, Equity, Viad, Walt Disney, IDEA, Woman, Korn Ferry, AI, Cigna, Kohl's, Warner Bros. Discovery, Partnership, Life, Spelman, Culture, Novartis, Bristol Myers Squibb, Zurich Insurance Group, Booz Allen Hamilton, LHH, Noise, AIG, Workforce, CDW, Digimarc, Student, Spelman College, Boston Scientific, Management

WASHINGTON, May 2, 2024 /PRNewswire/ --  Tapestry Networks' Inclusion, Diversity, and Equity in Action (IDEA) initiative, in partnership with Spelman College, a global leader in the education of women of African descent, will host Reimagining the Future of Talent, a dialogue on the convergence of talent, technology, corporate culture, and workforce equity as mobilizers of business strategy. Given profound differences between Fortune 100 directors and students entering the workforce, and rapidly changing employer-employee relationships, this forum arrives at a critical juncture as boards seek to respond to global forces shaping the future of work, and to create inclusive talent pathways in their companies.

Key Points: 
  • Talent can make or break a company, especially in uncertain times.
  • "Talent can make or break a company, especially in uncertain times," said Dr. Marsha H. Ershaghi, Managing Director, Tapestry Networks.
  • Directors want to push the pace of progress and want to get to know the priorities of the newest generations in the workforce."
  • Reimagining the Future of Talent will take place September 19, 2024, on Spelman College's Atlanta campus.

Risk Strategies Annual Education Practice Student Health Plan Survey Finds Controlling Cost Reemerges as Primary Concern; Student Mental Health Drops to Third

Retrieved on: 
목요일, 4월 25, 2024
Risk management, Cigna, School, Preferred provider organization, ACA, Mental health, Student, University

The survey results also showed mental health coverage continues to be a top-three priority for plan administrators.

Key Points: 
  • The survey results also showed mental health coverage continues to be a top-three priority for plan administrators.
  • The survey of approximately 140 colleges and universities, conducted midyear 2023, revealed that the average student health plan cost mean increase rose in 2023 by 4.7%.
  • In the past two years, student health plans had seen a full 5% rise in mean increase.
  • “In this third year of our annual survey, we see clear signs that student health plan administrators are looking not only at costs, but overall value,” said Terry Lyons, National Education Practice Leader, Risk Strategies.

50%+ of Medicare Eligibles Selected a Medicare Advantage Plan in 2024 per Mark Farrah Associates’ Report

Retrieved on: 
월요일, 4월 29, 2024
Insurance, Finance, Banking, Professional Services, Public Policy, Government, Healthcare Reform, General Health, Data Analytics, Pharmaceutical, Health, CVS, Humana, Cigna, PDP, MFA, UnitedHealth Group, Medicare, Health insurance

Mark Farrah Associates (MFA), www.markfarrah.com , recently assessed Medicare Advantage (MA), including Medicare Advantage with Prescription Drug Plan (MA-PD) and Prescription Drug Plan (PDP) performance, market share and market growth by state as of April 1, 2024.

Key Points: 
  • Mark Farrah Associates (MFA), www.markfarrah.com , recently assessed Medicare Advantage (MA), including Medicare Advantage with Prescription Drug Plan (MA-PD) and Prescription Drug Plan (PDP) performance, market share and market growth by state as of April 1, 2024.
  • Report findings indicate more than half of people eligible for Medicare selected a Medicare Advantage plan and another third selected a Part D - prescription drug plan in 2024.
  • Total MA membership exceeded 33.4 million and Medicare stand-alone PDPs covered nearly 22.7 million members.
  • Many companies conduct their post-OEP (Open Enrollment Period) competitive assessments by using tools such as Mark Farrah Associates’ (MFA) Medicare Business Online™, Medicare Benefits Analyzer™, and Health Coverage Portal™.

United States Pharmacy Benefit Management (PBM) Insights 2023-2024 & 2029: Claim Processing Emerges as Fastest-Growing Segment, Virtual Care and Home Services Fuel the $680 Million Market - ResearchAndMarkets.com

Retrieved on: 
월요일, 4월 29, 2024
Pharmaceutical, Health, Health Insurance, Spend, USD, Pharmacy, UnitedHealth Group, PBM, Insurance, CVS Health, Plasma protein binding, Cigna, Patient, Conditional sentence, Medicare, Taft–Hartley Act, Diagnosis, Growth, Fraud, Health care

CVS Health, Cigna Healthcare, United Health Group, Prime Therapeutics, MedImpact, and Humana dominate the U.S. Pharmacy Benefit Management market.

Key Points: 
  • CVS Health, Cigna Healthcare, United Health Group, Prime Therapeutics, MedImpact, and Humana dominate the U.S. Pharmacy Benefit Management market.
  • The major players focus on strategic acquisitions and collaborations with emerging players to enter the pharmacy benefit management market and gain a competitive advantage.
  • The southern region dominated the segment of the U.S. pharmacy benefit management (PBM) market, with a share of 30% in 2023.
  • The claim processing in the service segment is the fastest-growing in the U.S. pharmacy benefit management (PBM) market during the forecast period.

2024 Talent Experience Award Winners Celebrated at IAMPHENOM

Retrieved on: 
수요일, 4월 24, 2024
Manufacturing, Other Technology, Artificial Intelligence, Human Resources, Software, Finance, Internet, Banking, Professional Services, Technology, General Health, Public Relations, Investor Relations, Marketing, Health, Other Manufacturing, Communications, Other Travel, Transportation, Travel, Organization, Mastercard, Merck Group, ROI, Interview, Learning, Catholic Church, Transport, Mentorship, Hub, AI, Truist, Cigna, Retail, Communication, Partnership, HPE, HUGO, Intelligence, SAP SuccessFactors, Automation, HRIS, Acquisition, Financial services, Multimedia, CRM, Stanford University Medical Center, TD SYNNEX, Thermo Fisher Scientific, SAP, Growth, Architecture

Phenom today announced the 2024 Talent Experience award winners recognizing organizations’ extraordinary achievements using intelligence, automation and experience to hire, develop and retain employees.

Key Points: 
  • Phenom today announced the 2024 Talent Experience award winners recognizing organizations’ extraordinary achievements using intelligence, automation and experience to hire, develop and retain employees.
  • View the full release here: https://www.businesswire.com/news/home/20240424315989/en/
    2024 Talent Experience Award Winners celebrated at IAMPHENOM (April 23-25 in Philadelphia) recognizing organizations’ remarkable achievements using intelligence, automation and experience to hire, develop and retain employees.
  • (Photo: Business Wire)
    Award winners were announced onsite during IAMPHENOM , the human resources conference for talent acquisition, talent management, CHROs, HRIS and executives taking place in-person April 23-25 in Philadelphia.
  • Mastercard wanted an always-on, highly scalable global talent acquisition function that would deliver a modern, ‘consumer-like’ experience to talent prospects and applicants.

Axena Health receives two additional positive insurance coverage decisions for Leva

Retrieved on: 
목요일, 4월 11, 2024
Medical Devices, Women, FDA, Health Technology, Health Insurance, Biotechnology, Health, Consumer, Pharmaceutical, UI, Urinary incontinence, Woman, BCBS, Food, Cigna, The Institute, Leva, MD, Highmark, Life, Pelvic floor, Female, Pelvic organ prolapse, Privacy, Incontinence, Overactive bladder, Storey, MBA, FACOG, Food and Drug Administration, HCPCS, Nursing

Both positive coverage decisions became effective on April 1, 2024.

Key Points: 
  • Both positive coverage decisions became effective on April 1, 2024.
  • “Axena Health is focused on providing evidence-based solutions through both formal clinical trials with world-class academic institutions and published real-world evidence.
  • “Two more positive coverage decisions for the Leva System means more women can access effective, first-line treatment for UI.
  • Highmark BCBS and BCBS of ND have joined Cigna in demonstrating their clear commitment to women’s health.